Physician profile
Steven Lee Brown
NPI 1649615873
$104,951.31
in general payments reported to CMS, 2019-2025
55 companies · $60K in 2025
The $60K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,413 · 2020: $1,054 · 2021: $1,046 · 2022: $1,258 · 2023: $1,723 · 2024: $38K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76K · Travel and Lodging: $10K · Food and Beverage: $7,325 · Honoraria: $6,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,938.50 |
| Travel and Lodging | $10,173.41 |
| Food and Beverage | $7,324.69 |
| Honoraria | $6,745.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $54,301.12 | 2019-2025 | |
| Corcept Therapeutics | $29,550.63 | 2019-2025 | Korlym |
| Ascendis Pharma Endocrinology INC | $12,861.57 | 2025 | Yorvipath |
| Novo Nordisk INC | $1,052.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $963.02 | 2020-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $824.66 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $798.94 | 2019-2025 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $763.85 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $586.10 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $472.82 | 2019-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $251.71 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.56 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $224.65 | 2022-2025 | |
| Abbvie INC. | $214.53 | 2019-2025 | Synthroid |
| Insulet Corporation | $155.80 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.